Concepedia

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon, Boon Khaw Lim, Jin‐Ji Yang, Marie Wislez, Cheng Huang, Chong Kin Liam, Julien Mazieres, Lye Mun Tho,

The Lancet Oncology · 2024 · 86 citations · 23 references

DOIFull text

Open access

Concepts

References

23

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

, , +16

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck, Tony Mok, Makoto Nishio et al. · The Lancet Respiratory Medicine · 2019 · 939 citations

, , +17

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

David M. Jackman, William Pao, Gregory J. Riely et al. · Journal of Clinical Oncology · 2009 · 786 citations

, , +15

Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC

David Planchard, Pasi A. Jänne, Ying Cheng et al. · New England Journal of Medicine · 2023 · 650 citations · Full text

, , +7

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa et al. · The Lancet Oncology · 2015 · 410 citations

, , +15